JP5709818B2 - イオン性複合体 - Google Patents
イオン性複合体 Download PDFInfo
- Publication number
- JP5709818B2 JP5709818B2 JP2012237656A JP2012237656A JP5709818B2 JP 5709818 B2 JP5709818 B2 JP 5709818B2 JP 2012237656 A JP2012237656 A JP 2012237656A JP 2012237656 A JP2012237656 A JP 2012237656A JP 5709818 B2 JP5709818 B2 JP 5709818B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- complex
- acp
- phosphate
- acfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 claims description 99
- 102000007982 Phosphoproteins Human genes 0.000 claims description 94
- 108010089430 Phosphoproteins Proteins 0.000 claims description 94
- 239000001506 calcium phosphate Substances 0.000 claims description 59
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 59
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 57
- 235000011010 calcium phosphates Nutrition 0.000 claims description 57
- 239000011575 calcium Substances 0.000 claims description 55
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 51
- 229910052791 calcium Inorganic materials 0.000 claims description 51
- 229960005069 calcium Drugs 0.000 claims description 51
- 108010001441 Phosphopeptides Proteins 0.000 claims description 39
- 238000009472 formulation Methods 0.000 claims description 39
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 34
- 229910001424 calcium ion Inorganic materials 0.000 claims description 34
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 239000005018 casein Substances 0.000 claims description 24
- 208000002925 dental caries Diseases 0.000 claims description 23
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 22
- 235000021240 caseins Nutrition 0.000 claims description 21
- MFLAROGHONQVRM-UHFFFAOYSA-L calcium;dihydrogen phosphate;fluoride Chemical compound [F-].[Ca+2].OP(O)([O-])=O MFLAROGHONQVRM-UHFFFAOYSA-L 0.000 claims description 19
- 239000002131 composite material Substances 0.000 claims description 13
- 230000007797 corrosion Effects 0.000 claims description 11
- 238000005260 corrosion Methods 0.000 claims description 11
- 201000002170 dentin sensitivity Diseases 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 10
- 239000010452 phosphate Substances 0.000 claims description 10
- 230000003628 erosive effect Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 210000000214 mouth Anatomy 0.000 claims description 6
- 208000006558 Dental Calculus Diseases 0.000 claims description 5
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 5
- 239000001527 calcium lactate Substances 0.000 claims description 5
- 235000011086 calcium lactate Nutrition 0.000 claims description 5
- 229960002401 calcium lactate Drugs 0.000 claims description 5
- 230000000395 remineralizing effect Effects 0.000 claims description 4
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims description 3
- 229910001634 calcium fluoride Inorganic materials 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- GUYBGCBOZOALMT-UHFFFAOYSA-J dicalcium;fluoride;phosphate Chemical compound [F-].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O GUYBGCBOZOALMT-UHFFFAOYSA-J 0.000 claims 1
- 239000000606 toothpaste Substances 0.000 description 34
- 229940034610 toothpaste Drugs 0.000 description 25
- 108010076119 Caseins Proteins 0.000 description 22
- 102000011632 Caseins Human genes 0.000 description 22
- 210000003298 dental enamel Anatomy 0.000 description 22
- 239000000463 material Substances 0.000 description 20
- 230000003902 lesion Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- -1 phosphoseryl residue Chemical group 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 5
- 239000003082 abrasive agent Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- GFIKIVSYJDVOOZ-UHFFFAOYSA-L calcium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [Ca+2].[O-]P([O-])(F)=O GFIKIVSYJDVOOZ-UHFFFAOYSA-L 0.000 description 5
- 235000015218 chewing gum Nutrition 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 241000283725 Bos Species 0.000 description 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 4
- 206010044038 Tooth erosion Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005115 demineralization Methods 0.000 description 4
- 230000002328 demineralizing effect Effects 0.000 description 4
- 229950006137 dexfosfoserine Drugs 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003178 glass ionomer cement Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 125000005341 metaphosphate group Chemical group 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229940051866 mouthwash Drugs 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003479 dental cement Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 208000036595 non-bacterial tooth erosion Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- JLPAMKUIIFHLBH-UHFFFAOYSA-N 1,2-dihydroxypropane-1-sulfonic acid Chemical compound CC(O)C(O)S(O)(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical group CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 1
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229910018068 Li 2 O Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 229920006387 Vinylite Polymers 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 230000003095 anti-phagocytic effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010019954 casein phosphopeptide-amorphous calcium phosphate nanocomplex Proteins 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical class O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 235000015260 sugar-free gum Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical group [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910052845 zircon Inorganic materials 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
Description
齲蝕は、歯垢の歯病原性(odontopathogenic)細菌による食事性糖分の発酵から通常生じる有機酸による歯の硬質組織の脱灰によって開始される。齲蝕は依然として公衆衛生上の大きな問題である。さらに、修復した歯の表面は、修復部の縁部周囲がさらに齲蝕になり得る。大部分の先進国におけるフッ素の使用によって齲蝕の罹患率は低減してきてはいるものの、この疾患は依然として公衆衛生上の大きな問題となっている。歯の侵食/腐食は、食事性酸または逆流した酸による歯のミネラル分の喪失である。象牙質知覚過敏は、保護石灰化層の喪失により露出した象牙細管によるものであり、セメント質および歯石は、歯の表面へのリン酸カルシウムミネラルの望ましくない付着物である。従って、これらの全ての状態、齲蝕、歯の侵食/腐食、象牙質知覚過敏および歯石は、リン酸カルシウムレベルの不均衡である。齲蝕、歯の侵食/腐食、および象牙質知覚過敏は、失われたリン酸カルシウムを補うために生物学的に利用可能なカルシウムイオンおよびリン酸イオンを提供することにより、安定化された無定形リン酸カルシウム(ACP)を用いて処置され得る。安定化されたACPは、歯石の表面にも結合して、さらなる付着を防ぎ得る。従って、安定化されたACPおよび安定化された無定形リン酸フッ化カルシウム(ACFP)は、口腔疾患およびその他の医学的状態の予防および処置において大きな役割を果たし得る。
(項目1)
リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウムまたは無定形リン酸フッ化カルシウムの複合体であって、PP1モル当たりのカルシウムが約30モルよりも高いカルシウムイオン含量を有する、複合体。
(項目2)
前記PPがカゼインホスホペプチド(CPP)である、項目1に記載の複合体。
(項目3)
前記カルシウムイオン含量が、PP1モル当たりカルシウム30〜50モルの範囲内にある、項目1に記載の複合体。
(項目4)
項目1に記載の複合体を含む、口腔ケア配合物。
(項目5)
リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)および/または無定形リン酸フッ化カルシウム(ACFP)の複合体であってPP1モル当たりのカルシウムが約30モルよりも高いカルシウムイオン含量を有する複合体を生成するための方法であって、
(i)PP−ACPおよび/またはPP−ACFPの複合体を含む溶液を得る工程;ならびに
(ii)該溶液のpHを7未満に保持しながらカルシウムイオンおよびリン酸イオンと混合する工程
を包含する、方法。
(項目6)
PPによって安定化されたACPおよび/またはACFPの複合体を少なくとも等重量のリン酸カルシウムと一緒にした配合物。
(項目7)
前記リン酸カルシウムがCaHPO 4 の形態にある、項目6に記載の配合物。
(項目8)
項目7に記載の配合物を含む、口腔ケア配合物。
(項目9)
歯の表面または表層下を再石灰化するための方法であって、リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウムまたは無定形リン酸フッ化カルシウムの複合体を該歯の表面または表層下に適用する工程を包含し、該複合体がPP1モル当たりカルシウム約30モルより高いカルシウムイオン含量を有する、方法。
(項目10)
ヒトを含む動物における齲蝕、歯の侵食/腐食、象牙質知覚過敏および歯石の1つ以上を処置および/または予防する方法であって、リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウムまたは無定形リン酸フッ化カルシウムの複合体を歯の表面または表層下に適用する工程を包含し、該複合体がPP1モル当たりカルシウム約30モルより高いカルシウムイオン含量を有する、方法。
(発明の要旨)
一態様において、本発明は「超増量」リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)または無定形リン酸フッ化カルシウム(ACFP)の複合体を提供する。この複合体は、任意のpH(例えば、3〜10)で形成され得る。好ましくは、リンペプチドは、配列−A−B−C−(この場合、Aはホスホアミノ酸、好ましくはホスホセリンであり;Bはホスホアミノ酸を含む任意のアミノ酸であり;Cはグルタメート、アスパルテートまたはホスホアミノ酸である)を含む。ホスホアミノ酸はホスホセリンであり得る。PPは、カルシウムイオンおよびリン酸イオンが超増量されている。カルシウムイオンは、PP1モル当たりCaが30〜1,000モルの範囲内にあり得るか、またはPP1モル当たりCaが30〜100モルもしくは30〜50の範囲内にあり得る。別の実施形態において、PP1モル当たりのCaのモル数は、少なくとも25、30、35、40、45または50である。リン酸イオンは一般的に、カルシウムイオンに対する比率(Ca:P)が1.5〜1.8:1にて存在する。1つの実施形態において、この比は約1.58:1である。
(i)カルシウム、無機リン酸塩およびフッ化物(場合による)を含む溶液を得る工程;ならびに
(ii)PP−ACPを含む溶液と(i)を混合する工程
を包含する方法も提供する。
(i)カルシウム、無機リン酸塩およびフッ化物(場合による)からなる溶液を得る工程;ならびに
(ii)PP−ACPおよび/またはPP−ACFPを含む溶液と(i)を混合する工程;
あるいは
(i)カルシウム(例えば、CaHPO4、乳酸カルシウム等)を含む粉末を得る工程;ならびに
(ii)PP−ACPおよび/またはPP−ACFP粉末と(i)を混合する工程
を包含する方法が提供される。
(i)PP−ACPおよび/またはPP−ACFPの複合体を含む溶液を得る工程;
(ii)溶液のpHを7未満に保持しながらカルシウムおよびリン酸イオンと混合する工程
を包含する方法が提供される。
(i)PP−ACPおよび/またはPP−ACFPの複合体を含む粉末を得る工程;
(ii)有効量のリン酸カルシウムと乾燥混合させる工程;ならびに
(iii)乾燥混合されたPP−ACPおよび/またはPP−ACFPおよびリン酸カルシウム混合物を口腔ケア配合物に配合する工程
を包含する方法が提供される。
(実施例1)
RecaldentTM(CPP−ACP)は、オーストラリア ビクトリアのRecaldent Pty Ltd.から販売されたものである。この製品(#841117)は、14.3重量%のカルシウム、22.3重量%のリン酸塩、および47重量%のカゼインホスホペプチドを含んでいた。この製品を0.5%溶解し、HClを添加してpH5.5に調節した。次いで、2.5MのNaOHを添加してpHを5.5に維持しながら、3.25MのCaCl2および2MのNaH2PO4を滴下することにより、カルシウムおよびリン酸イオンを添加した。この溶液が半透明になるまで、カルシウムおよびリン酸イオンの滴下を続けた。添加したカルシウムとリン酸塩の濃度を記録した。この溶液は又、カルシウムおよびリン酸イオンを0.5%のCPP−ACP溶液に滴下し、さらにリン酸カルシウムを添加してpHを5.5に低下させることによっても形成され得る。
別の実施例においては、RecaldentTM(CPP−ACP)粉末をCaHPO4粉末と、CPP−ACP:CaHPO4=1:10の重量比で乾燥混合させた。次いで、この粉末を無糖のガムおよび練り歯磨き配合物に1〜5重量/重量%で添加した。
通常CPP−ACPおよび超増量CPP−ACP(sCPP−ACP)によるインビトロにおけるエナメル質表層下病変の再石灰化の比較
抜歯したヒト第3大臼歯の研磨したエナメル質表層を、鋸でひいて平板(8×4mm2)に切断し、酸耐性マニキュア液を被覆して、1mmの間隔をおいた咬合側半分および歯肉側半分の近遠心窓(1×7mm2)を形成した(Reinolds E.C. (1997) J. Dent. Res. 76, 1587−1595)。これらの窓の中に表層下エナメル質病変を、Reinolds(Reinolds E.C. (1997) J. Dent. Res. 76, 1587−1595)が改良したWhiteのCarbopol法(White D.J. (1987) Caries Res 21, 228−242)を使用して作り出した。エナメル質の平板を鋸で半分に切断し、4×4mm2ブロックを形成した。一方のブロックの歯肉側半分の病変と他方のブロックの咬合側半分病変にマニキュアで封止し、Reinolds(Reinolds E.C. (1997) J. Dent. Res. 76, 1587−1595)に記載の通りに脱灰対照を作り出した。
超増量CPP−ACP(sCPP−ACP)を含む練り歯磨き配合物がエナメル質表層下病変を再石灰化する能力を、Reinolds等(Reinolds E.C., et al. (2003) J. Dent Res. 82, 206−211)のプロトコールを使用し、インサイチュ無作為クロスオーバー二重盲検臨床試験にて調査した。10人の対象が、実施例3に記載の通り調製した表層下の脱灰病変を含む6つのヒトエナメル質の半分の平板片を使用した取り外し可能な口蓋装置を装着した。各エナメル質のもう半分の平板を加湿容器中に保存し、対照脱灰病変として使用した。この試験では以下の7つの処置を行った:即ち、0.2重量/重量%の通常CPP−ACPを含む練り歯磨きB;0.2%のCPP−ACP/1.0%のCaHPO4を含む練り歯磨きC(図2および実施例5では「1.2%のsCPP−ACP」を呼ばれる);1.0%のCaHPO4を含む練り歯磨きE;1,000ppmのFを含む練り歯磨きF;1.2%のsCPP−ACPおよび1,000ppmのFを含む練り歯磨きG;0.2%のCPP−ACP/1.8%のCaHPO4を含む練り歯磨きD(図2および実施例5では「2.0%のsCPP−ACP」と呼ばれる);および対照練り歯磨きA(プラセボ)。これらの練り歯磨きを1日に4回30秒ずつ使用した。装置は、練り歯磨きの使用中および該練り歯磨きの使用後1時間、装着した。各処置を14日間続け、10人の対象それぞれが、各処置の間に1週間の休みを入れながら、各処置を行った。各処置の完了時にエナメル質平板を取り出し、それらの各々の脱灰対照と対にして、埋込みおよび切片化を行い、マイクロラジオグラフィーならびにコンピュータによるデンシトメトリー画像解析にかけて、再石灰化のレベルを測定した。エナメル質の再石灰化の百分率(%R)として示した結果は、図2に示されており;1.0%のCaHPO4(1.2%のsCPP−ACP)または1.8%のCaHPO4(2.0%のsCPP−ACP)の何れかを超増量した0.2%のCPP−ACPが、同じ濃度の通常の0.2%CPP−ACPまたはCaHPO4単独よりも、エナメル質表層下病変を有意に再石灰化することを示している。2.0%のsCPP−ACPのペーストは、1,000ppmのフッ化物を含むペーストよりも有意に優れていた。さらに、1.2%のsCPP−ACPおよび1,000ppmのFは、1.2%のsCPP−ACPまたは1,000ppmのF単独よりも、さらなる効果を示した。
超増量CPP−ACP(sCPP−ACP)を含む練り歯磨き配合物
Claims (16)
- リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)または無定形リン酸フッ化カルシウム(ACFP)の複合体であって、PP1モル当たりのカルシウムが30モル以上のカルシウムイオン含量を有する、複合体。
- リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)または無定形リン酸フッ化カルシウム(ACFP)の複合体であって、PP1モル当たりのカルシウムが30モル以上のカルシウムイオン含量を有し、
(i)PP−ACPおよび/またはPP−ACFPの複合体を含む溶液を得る工程;ならびに
(ii)該溶液のpHを7未満に保持しながらカルシウムイオンおよびリン酸イオンと混合する工程
を包含する工程によって生成される、複合体。 - 前記PPがカゼインホスホペプチド(CPP)である、請求項1または2に記載の複合体。
- 前記複合体のカルシウムイオン含量が、PP1モル当たりカルシウム30〜100モルの範囲内にある、請求項1から3のいずれか1項に記載の複合体。
- 前記複合体のカルシウムイオン含量が、PP1モル当たりカルシウム30〜50モルの範囲内にある、請求項1から3のいずれか1項に記載の複合体。
- 請求項1から5のいずれか1項に記載の複合体を含む、口腔ケア配合物。
- 前記複合体と少なくとも等重量のリン酸カルシウムまたは乳酸カルシウムをさらに含む、請求項6に記載の口腔ケア配合物。
- 水性である、請求項6または7に記載の口腔ケア配合物。
- リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)および/または無定形リン酸フッ化カルシウム(ACFP)の複合体であってPP1モル当たりのカルシウムが30モル以上のカルシウムイオン含量を有する複合体を生成するための方法であって、
(i)PP−ACPおよび/またはPP−ACFPの複合体を含む溶液を得る工程;ならびに
(ii)該溶液のpHを7未満に保持しながらカルシウムイオンおよびリン酸イオンと混合する工程
を包含する、方法。 - リンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)および/または無定形リン酸フッ化カルシウム(ACFP)の複合体を少なくとも等重量のリン酸水素カルシウムまたは乳酸カルシウムと一緒にした配合物。
- 前記PPによって安定化された無定形リン酸カルシウム(ACP)および/または無定形リン酸フッ化カルシウム(ACFP)の複合体:リン酸水素カルシウムの重量比が1:10である、請求項10に記載の配合物。
- 請求項10または11に記載の配合物を含む、口腔ケア配合物。
- 口腔内で使用するときにリンペプチドまたはリンタンパク質(PP)1モル当たりのカルシウムが30モル以上のカルシウムイオン含量を有する、PPによって安定化された無定形リン酸カルシウム(ACP)および/または無定形リン酸フッ化カルシウム(ACFP)の複合体を含む口腔ケア配合物を生成する方法であって、
(i)PP−ACPおよび/またはPP−ACFPの複合体を含む粉末を得る工程;
(ii)有効量のリン酸水素カルシウムまたは乳酸カルシウムと乾燥混合させる工程;ならびに
(iii)乾燥混合されたPP−ACPおよび/またはPP−ACFPおよびリン酸カルシウム混合物を口腔ケア配合物に配合する工程
を包含する方法。 - 請求項13に記載の方法により生成される口腔ケア配合物。
- 歯の表面または表層下を再石灰化するための口腔ケア配合物であって、該配合物は請求項1から5のいずれか1項に記載のリンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)または無定形リン酸フッ化カルシウム(ACFP)の複合体を活性成分として含有し、該複合体がPP1モル当たりのカルシウムが30モル以上のカルシウムイオン含量を有する、口腔ケア配合物。
- 齲蝕、歯の侵食/腐食、象牙質知覚過敏および歯石の1つ以上を処置および/または予防するための口腔ケア配合物であって、該配合物は請求項1から5のいずれか1項に記載のリンペプチドまたはリンタンパク質(PP)によって安定化された無定形リン酸カルシウム(ACP)または無定形リン酸フッ化カルシウム(ACFP)の複合体を活性成分として含有し、該複合体がPP1モル当たりのカルシウムが30モル以上のカルシウムイオン含量を有する、口腔ケア配合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69401905P | 2005-06-24 | 2005-06-24 | |
US60/694,019 | 2005-06-24 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008517280A Division JP2008543887A (ja) | 2005-06-24 | 2006-06-23 | イオン性複合体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013028644A JP2013028644A (ja) | 2013-02-07 |
JP2013028644A5 JP2013028644A5 (ja) | 2013-08-08 |
JP5709818B2 true JP5709818B2 (ja) | 2015-04-30 |
Family
ID=37570039
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008517280A Withdrawn JP2008543887A (ja) | 2005-06-24 | 2006-06-23 | イオン性複合体 |
JP2012237656A Active JP5709818B2 (ja) | 2005-06-24 | 2012-10-29 | イオン性複合体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008517280A Withdrawn JP2008543887A (ja) | 2005-06-24 | 2006-06-23 | イオン性複合体 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8603988B2 (ja) |
EP (1) | EP1901702B1 (ja) |
JP (2) | JP2008543887A (ja) |
CN (1) | CN101208070B (ja) |
AR (1) | AR057402A1 (ja) |
AU (1) | AU2006261597B2 (ja) |
BR (1) | BRPI0611976B1 (ja) |
CA (1) | CA2612172C (ja) |
ES (1) | ES2530396T3 (ja) |
MX (1) | MX2007016312A (ja) |
NZ (1) | NZ564129A (ja) |
PL (1) | PL1901702T3 (ja) |
RU (1) | RU2413497C2 (ja) |
WO (1) | WO2006135982A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005309327B2 (en) | 2004-11-25 | 2010-11-25 | The University Of Melbourne | Stabilized calcium phosphate complexes |
EP1901702B1 (en) * | 2005-06-24 | 2014-11-26 | The University of Melbourne | Ionic complexes |
WO2007090242A1 (en) | 2006-02-09 | 2007-08-16 | The University Of Melbourne | Fluoride composition and methods for dental mineralization |
AU2007235360B2 (en) | 2006-04-05 | 2010-11-25 | Intercontinental Great Brands Llc | Impact of calcium phosphate complex on dental caries |
US20070237855A1 (en) * | 2006-04-05 | 2007-10-11 | Cadbury Adams Usa Llc | Calcium phosphate complex in acid containing confectionery |
AU2007235359B2 (en) * | 2006-04-05 | 2011-03-10 | Intercontinental Great Brands Llc | Calcium phosphate complex and salts in oral delivery systems |
WO2008153725A2 (en) | 2007-05-25 | 2008-12-18 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
DE102008014227A1 (de) * | 2008-03-16 | 2009-10-01 | Nova Dentalia Zahnpflege Gmbh | Remineralisierende Speichelersatzmittel und Verfahren zu deren Herstellung |
DE102008014225A1 (de) * | 2008-03-16 | 2009-09-17 | MEDERER Süßwarenvertriebs GmbH | Remineralisierende Zahnpflegemittel und Verfahren zu deren Herstellung |
JP2010047494A (ja) * | 2008-08-20 | 2010-03-04 | Gc Corp | 歯牙塗布用組成物 |
WO2010042754A2 (en) * | 2008-10-08 | 2010-04-15 | Medical College Of Georgia Research Institute, Inc. | Methods and systems for mineralization of demineralized tissue |
GB0908433D0 (en) * | 2009-05-15 | 2009-06-24 | Glaxo Group Ltd | Movel composition |
CN102946889B (zh) * | 2010-03-31 | 2015-05-06 | 东洋水产株式会社 | 钙剂及其制造方法 |
AU2011293349B2 (en) | 2010-08-24 | 2014-04-03 | Safewhite, Inc. | Methods and materials for providing teeth with a white appearance |
US9107838B2 (en) | 2012-04-25 | 2015-08-18 | Therametrics Technologies, Inc. | Fluoride varnish |
CN117717569A (zh) * | 2013-07-05 | 2024-03-19 | 恒星生物群落有限公司 | 口服组合物 |
CN105530909A (zh) | 2013-07-23 | 2016-04-27 | 墨尔本大学 | 用于牙齿矿化的组合物及方法 |
MY176788A (en) | 2013-12-24 | 2020-08-21 | Univ Melbourne | Stabilized stannous compositions |
JP2016102069A (ja) * | 2014-11-27 | 2016-06-02 | 株式会社ジーシー | 歯面清掃方法、歯面清掃用組成物、及びその使用方法 |
KR20170100580A (ko) * | 2014-12-24 | 2017-09-04 | 더 유니버시티 오브 멜버른 | 광화 플루오라이드 조성물 |
US11696879B2 (en) | 2016-05-26 | 2023-07-11 | 3M Innovative Properties Company | Therapeutic dental pastes and related methods and kits |
CN107811872B (zh) * | 2016-09-13 | 2020-09-15 | 北京大学 | 一种快速牙釉质矿化的方法 |
US12109284B2 (en) | 2016-11-08 | 2024-10-08 | Dentherapy Ltd | Compositions comprising fluoride and calcium and method for preparing them |
KR101772449B1 (ko) | 2016-12-27 | 2017-08-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
JP7142943B2 (ja) | 2017-03-14 | 2022-09-28 | ザ ユニバーシティー オブ メルボルン | 歯肉炎の処置 |
CN108524290A (zh) * | 2018-06-28 | 2018-09-14 | 吉林省登泰克牙科材料有限公司 | 牙科预防龋齿组合物及其制备方法 |
JP7352626B2 (ja) * | 2019-05-27 | 2023-09-28 | 株式会社ジーシー | 歯科用キット及びう蝕の予防方法 |
US20220273522A1 (en) | 2019-07-04 | 2022-09-01 | Ferton Holding S.A. | Composition for the remineralization of teeth |
EP4034072A4 (en) * | 2019-09-25 | 2023-11-08 | Church & Dwight Co., Inc. | ORAL CARE COMPOSITION |
CN111715408B (zh) * | 2020-06-30 | 2021-07-02 | 中南大学 | 一种用于浮选白钨矿中萤石的浮选药剂及其浮选方法 |
GB202010987D0 (en) | 2020-07-16 | 2020-09-02 | Dentherapy Ltd | Oral care compositions and methods |
GB202110114D0 (en) | 2021-07-14 | 2021-08-25 | Dentherapy Ltd | Oral care compositions for use in treaatment |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522805A (en) | 1983-06-08 | 1985-06-11 | Norman Gordon | Tooth and gum dentifrice |
CA1315480C (en) * | 1986-06-12 | 1993-03-30 | Eric Charles Reynolds | Phosphopeptides |
US5015628A (en) * | 1986-06-12 | 1991-05-14 | The University Of Melbourne | Anticariogenic phosphopeptides |
US6056930A (en) | 1989-05-24 | 2000-05-02 | American Dental Association Health Foundation | Methods and compositions for mineralizing and fluoridating calcified tissues |
US5227154A (en) | 1991-08-22 | 1993-07-13 | The University Of Melbourne | Phosphopeptides for the treatment of dental calculus |
DE69327845T2 (de) | 1992-06-29 | 2000-10-26 | The University Of Melbourne, Parkville | Behandlung von empfindlichen zähnen |
JP2975337B2 (ja) | 1997-02-20 | 1999-11-10 | 雪印乳業株式会社 | カルシウム複合体 |
AUPO566297A0 (en) * | 1997-03-13 | 1997-04-10 | University Of Melbourne, The | Calcium phosphopeptide complexes |
JP3742523B2 (ja) | 1998-02-27 | 2006-02-08 | 雪印乳業株式会社 | 高分子型カルシウム・ホスホペプチド複合体 |
FR2791573B1 (fr) | 1999-03-30 | 2003-04-11 | Pf Medicament | Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate |
US6521215B2 (en) | 1999-05-28 | 2003-02-18 | Devin Okay | Compositions and methods for tooth treatment |
US6685920B2 (en) | 1999-11-12 | 2004-02-03 | The Procter & Gamble Company | Method of protecting teeth against erosion |
GB9929919D0 (en) | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
AUPR517701A0 (en) * | 2001-05-21 | 2001-06-14 | University Of Melbourne, The | Dental restorative materials |
MXPA04006541A (es) | 2002-01-03 | 2004-10-04 | Procter & Gamble | Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluoruro. |
EP1461006B1 (en) | 2002-01-03 | 2016-09-28 | The Procter & Gamble Company | Stable oral compositions comprising casein phosphopeptide complexes and fluoride |
NZ522071A (en) | 2002-10-18 | 2005-07-29 | Patrick Joseph Silcock | Hydrolysed casein phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation |
JP4340069B2 (ja) * | 2003-01-10 | 2009-10-07 | 雪印乳業株式会社 | カルシウム複合体の製造法 |
US20050089481A1 (en) * | 2003-10-23 | 2005-04-28 | Gc Corporation | Composition for caries prevention |
ES2399345T3 (es) | 2005-06-07 | 2013-03-27 | The University Of Melbourne | Mineralización dental |
EP1901702B1 (en) * | 2005-06-24 | 2014-11-26 | The University of Melbourne | Ionic complexes |
-
2006
- 2006-06-23 EP EP06752630.1A patent/EP1901702B1/en active Active
- 2006-06-23 PL PL06752630T patent/PL1901702T3/pl unknown
- 2006-06-23 RU RU2008102637/15A patent/RU2413497C2/ru active
- 2006-06-23 MX MX2007016312A patent/MX2007016312A/es active IP Right Grant
- 2006-06-23 BR BRPI0611976-0A patent/BRPI0611976B1/pt active IP Right Grant
- 2006-06-23 NZ NZ564129A patent/NZ564129A/en unknown
- 2006-06-23 AU AU2006261597A patent/AU2006261597B2/en active Active
- 2006-06-23 CN CN2006800227822A patent/CN101208070B/zh active Active
- 2006-06-23 ES ES06752630T patent/ES2530396T3/es active Active
- 2006-06-23 JP JP2008517280A patent/JP2008543887A/ja not_active Withdrawn
- 2006-06-23 AR ARP060102716A patent/AR057402A1/es active IP Right Grant
- 2006-06-23 WO PCT/AU2006/000885 patent/WO2006135982A1/en active Application Filing
- 2006-06-23 US US11/917,395 patent/US8603988B2/en active Active
- 2006-06-23 CA CA2612172A patent/CA2612172C/en active Active
-
2012
- 2012-10-29 JP JP2012237656A patent/JP5709818B2/ja active Active
-
2013
- 2013-11-07 US US14/074,022 patent/US9241883B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1901702A1 (en) | 2008-03-26 |
BRPI0611976B1 (pt) | 2018-07-10 |
AU2006261597A1 (en) | 2006-12-28 |
MX2007016312A (es) | 2008-03-05 |
BRPI0611976A2 (pt) | 2010-10-13 |
US20100215593A1 (en) | 2010-08-26 |
RU2413497C2 (ru) | 2011-03-10 |
JP2008543887A (ja) | 2008-12-04 |
CN101208070A (zh) | 2008-06-25 |
NZ564129A (en) | 2010-02-26 |
CN101208070B (zh) | 2011-08-31 |
AR057402A1 (es) | 2007-12-05 |
AU2006261597B2 (en) | 2011-06-23 |
ES2530396T3 (es) | 2015-03-02 |
EP1901702B1 (en) | 2014-11-26 |
CA2612172C (en) | 2013-05-14 |
PL1901702T3 (pl) | 2015-07-31 |
EP1901702A4 (en) | 2012-01-18 |
US9241883B2 (en) | 2016-01-26 |
CA2612172A1 (en) | 2006-12-28 |
WO2006135982A1 (en) | 2006-12-28 |
US8603988B2 (en) | 2013-12-10 |
US20140056824A1 (en) | 2014-02-27 |
RU2008102637A (ru) | 2009-07-27 |
JP2013028644A (ja) | 2013-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5709818B2 (ja) | イオン性複合体 | |
JP5000525B2 (ja) | 安定化したリン酸カルシウム複合体 | |
JP4541455B2 (ja) | カルシウムホスホペプチド複合体 | |
US11564873B2 (en) | Stabilized stannous compositions | |
JP2019218365A (ja) | 歯の石灰化のための組成物および方法 | |
JP2018502099A (ja) | 石灰化フルオリド組成物 | |
AU746314B2 (en) | Calcium phosphopeptide complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140604 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150303 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5709818 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |